Maternal serum perlecan levels in women with preeclampsia
| dc.contributor.author | Akbas M. | |
| dc.contributor.author | Koyuncu F.M. | |
| dc.contributor.author | Artunc-Ulkumen B. | |
| dc.contributor.author | Taneli F. | |
| dc.contributor.author | Ozdemir H. | |
| dc.date.accessioned | 2025-04-10T11:06:40Z | |
| dc.date.available | 2025-04-10T11:06:40Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Objective: Perlecan is an extracellular matrix proteoglycan suggested to maintain endothelial functions. We aimed to measure maternal serum perlecan levels in different preeclampsia phenotypes. Methods: This study included 50 women with preeclampsia and 30 healthy pregnant women. Results: Serum perlecan levels were significantly higher (p = 0.016) in preeclamptic women with severe features(n = 23) than preeclampsia patients(n = 27). There were no statistically significant differences in serum perlecan levels between the early-onset preeclampsia(n = 25), late-onset preeclampsia(n = 25), and healthy pregnancies. Conclusion: Our findings suggest that preeclamptic women with severe features have higher serum perlecan levels than women with preeclampsia. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. | |
| dc.identifier.DOI-ID | 10.1080/10641955.2019.1711390 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/46849 | |
| dc.publisher | Taylor and Francis Ltd | |
| dc.title | Maternal serum perlecan levels in women with preeclampsia | |
| dc.type | Article |